Trigger Finger
Conditions
Brief summary
Steroid injection is the first line treatment for trigger finger. Steroid injection is sometimes mixed with a local anesthetic.
Detailed description
The treatment of trigger finger involves an injection of corticosteroid. Corticosteroid treats the underlying inflammatory pathology. Some surgeons add lidocaine with epinephrine as a local anesthetic with the injection. Lidocaine with epinephrine is associated with a burning sensation and may be the primary pain associated with the injection. We hypothesize that a corticosteroid injection without lidocaine with epinephrine will be less painful, and equally effective in treating trigger finger
Interventions
Trigger finger injection
Trigger finger injection
Sponsors
Study design
Eligibility
Inclusion criteria
* At least 18 years old with trigger finger
Exclusion criteria
* Preference for open trigger finger release * Not a candidate for corticosteroid injection * Contraindication to lidocaine with epinephrine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain Outcome: Visual Analog Scale | Assessed 1 minute after injection (in clinic) | Assessed using the visual analog scale (0-10 scale). Zero indicates no pain, 10 indicates worst pain ever |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Corticosteroid With Lidocaine With Epinephrine This arm includes an injection mixture of corticosteroid and lidocaine with epinephrine
Corticosteroid with lidocaine with epinephrine: Trigger finger injection | 57 |
| Corticosteroid With Normal Saline This arm includes a mixture of corticosteroid and normal saline. The purpose of normal saline is the keep the volume and concentration similar when compared to the injections containing lidocaine.
Corticosteroid with normal saline: Trigger finger injection | 53 |
| Total | 110 |
Baseline characteristics
| Characteristic | Corticosteroid With Normal Saline | Total | Corticosteroid With Lidocaine With Epinephrine |
|---|---|---|---|
| Age, Continuous | 66 years | 64.3 years | 62.7 years |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Region of Enrollment United States | 53 participants | 110 participants | 57 participants |
| Sex: Female, Male Female | 3 Participants | 5 Participants | 2 Participants |
| Sex: Female, Male Male | 50 Participants | 105 Participants | 55 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 57 | 0 / 53 |
| other Total, other adverse events | 0 / 57 | 0 / 53 |
| serious Total, serious adverse events | 0 / 57 | 0 / 53 |
Outcome results
Pain Outcome: Visual Analog Scale
Assessed using the visual analog scale (0-10 scale). Zero indicates no pain, 10 indicates worst pain ever
Time frame: Assessed 1 minute after injection (in clinic)
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Corticosteroid With Lidocaine With Epinephrine | Pain Outcome: Visual Analog Scale | 3.5 score on a scale |
| Corticosteroid With Normal Saline | Pain Outcome: Visual Analog Scale | 2 score on a scale |
Pain Outcome: Visual Analog Scale
Assessed using the visual analog scale (0-10 scale). Zero indicates no pain, 10 indicates worst pain ever
Time frame: Assessed after 24 hours after injection (by phone)
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Corticosteroid With Lidocaine With Epinephrine | Pain Outcome: Visual Analog Scale | 1.2 units on a scale |
| Corticosteroid With Normal Saline | Pain Outcome: Visual Analog Scale | 1 units on a scale |